Quantcast
Last updated on April 18, 2014 at 14:59 EDT

Latest Tyrosine kinase receptors Stories

2013-04-22 14:18:26

Union with Shc keeps potential troublemaker away from bad company and out of the nucleus A protein which is intimately involved in cancer-promoting cell signaling also keeps a key component of the signaling pathway tied down and inactive, a team led by scientists from The University of Texas MD Anderson Cancer Center reports this week in Nature Structural Molecular Biology. Shc, pronounced "schick," plays a key role in activating signals which lead to cell proliferation (and cancer)...

2013-04-10 08:32:36

Study Presented at AACR 2013 Examines Bispecific Antibody in Combination with Paclitaxel and Trastuzumab CAMBRIDGE, Mass., April 10, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced preclinical study results showing that the novel bispecific therapy MM-111 restored tumor sensitivity to the chemotherapy agent, paclitaxel, and HER2-targeted treatment, trastuzumab, in a HER2+ gastric cancer model. The research was presented as part of the American...

2013-04-08 12:28:40

NT-113 is an Irreversible, Selective Pan-ErbB Tyrosine Kinase Inhibitor with Significant Capacity to Cross Blood Brain Barrier MENLO PARK, Calif., April 8, 2013 /PRNewswire/ -- Preclinical data showing high potency, excellent pharmacokinetics and single-agent anti-cancer activity of NT-113, a novel irreversible Pan-ErbB Tyrosine Kinase Inhibitor under development by NewGen Therapeutics, was presented in a poster session today at the American Association of Cancer Research Meeting in...

Reshaping Chemo Drugs Helps Them Target And Attack Cancer Cells
2013-02-28 11:10:10

Watch the video "Chemotherapy Drugs Getting Better at Targeting Cancer Cells" redOrbit Staff & Wire Reports - Your Universe Online Changing the shape of chemotherapy drug nanoparticles to make them rod-shaped rather than spherical can enhance their effectiveness in targeting and treating breast cancer cells by as much as 10,000-fold, according to new research from bioengineers at the University of California, Santa Barbara (UCSB). As part of the research, a team led by Samir...

Targeting Cancer With New Microscopy Technique
2013-02-26 12:58:30

University of Akron For scientists to improve cancer treatments with targeted therapeutic drugs, they need to be able to see proteins prevalent in the cancer cells. This has been impossible, until now. Thanks to a new microscopy technique, University of Akron researcher Dr. Adam Smith, assistant professor of chemistry, has observed how clusters of epidermal growth factor receptor (EGFR) – a protein abundant in lung and colon cancers, glioblastoma and others – malfunctions in...

2013-02-07 15:25:23

A new approach mimicking the body's natural defenses could help treat a therapy-resistant breast cancer Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are...

A Traffic Cop For Stopping Cancer Cells?
2013-01-15 05:53:23

Connie K. Ho for redOrbit.com — Your Universe Online Researchers from the Fox Chase Cancer Center recently discovered a novel method of improving cancer drugs, where they could block a specific pathway in the cell and provide an easier way for drugs to eliminate tumors. According to the American Cancer Society, cancer occurs when there is uncontrolled growth and expansion of abnormal cells. It is caused by external factors (such as chemicals, infectious organisms, radiation, and...

2012-10-02 02:30:25

CAMBRIDGE, Mass., Oct. 2, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the presentation of Phase 1 safety and clinical results evaluating two potential new therapies with a novel target - ErbB3, a signaling receptor believed to be responsible for triggering tumor growth and resistance in a number of malignancies including breast, ovarian, gastric, esophageal and bladder cancers. The two studies were presented in poster sessions at the European Society...

2012-09-18 06:29:30

CAMBRIDGE, Mass., Sept. 18, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that research evaluating two novel compounds for advanced cancers, including breast, ovarian, gastric and bladder, will be presented at the ESMO 2012 Congress (European Society for Medical Oncology ), Sept. 28 - Oct. 2 in Vienna, Austria. The medicines are some of the first therapies developed using Merrimack's proprietary scientific approach - Network Biology - focusing not on gene...

2012-09-05 21:19:07

A more-sensitive method to analyze protein interactions has uncovered a new way that cancer cells may use the cell-surface molecule HER3 to drive tumor progression following treatment with HER1 and HER2 inhibitors. The HER family of receptors has been linked to the development of a wide variety of human cancers. HER1 inhibitors such Iressa and HER2 inhibitors such as Herceptin are commonly used in the clinic for treatment of small cell lung carcinoma and breast cancer. A recent study...